About Trillium Therapeutics (TSE:TR)
Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolTSE:TR
CUSIPN/A
Phone+1-416-5950627
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-259.65%
Return on Assets-55.25%
Miscellaneous
EmployeesN/A
Outstanding Shares64,470,000
Trillium Therapeutics (TSE:TR) Frequently Asked Questions
What is Trillium Therapeutics' stock symbol?
Trillium Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TR."
How were Trillium Therapeutics' earnings last quarter?
Trillium Therapeutics Inc (TSE:TR) announced its quarterly earnings results on Friday, March, 9th. The company reported ($0.91) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.06) by $0.15. View Trillium Therapeutics' Earnings History.
When is Trillium Therapeutics' next earnings date?
Who are some of Trillium Therapeutics' key competitors?
Some companies that are related to Trillium Therapeutics include Horizon North Logistics (HNL), Imperial Metals (III), Reitmans (RET), Redknee Solutions (RKN), Absolute Software (ABT), CRH Medical (CRH), Crew Energy (CR), 5N Plus (VNP), Airboss of America (BOS), GMP Capital (GMP), Rocky Mountain Dealerships (RME), Cona Resources (CONA), Aimia (AIM), Storm Resources (SRX), Acasta Enterprises (AEF), Kelt Exploration LNG (RTK), Wesdome Gold Mines (WDO) and Inovalis REIT (INO.UN).
Who are Trillium Therapeutics' key executives?
Trillium Therapeutics' management team includes the folowing people:
- Calvin R. Stiller M.D., Independent Chairman of the Board
- Niclas Stiernholm, President, Chief Executive Officer, Director
- James T. Parsons, Chief Financial Officer
- Malik Slassi, Senior Vice President - Discovery Research
- Robert Uger, Chief Scientific Officer
- Scott Duncan, Director of Intellectual Property
- Penka Petrova, Chief Development Officer
- Eric L Sievers, Chief Medical Officer
- Luke M. Beshar CPA, Independent Director (Age 59)
- Henry Friesen M.D., Independent Director (Age 79)
Has Trillium Therapeutics been receiving favorable news coverage?
Media headlines about TR stock have trended somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Trillium Therapeutics earned a daily sentiment score of 0.21 on Accern's scale. They also assigned media headlines about the company an impact score of 46.72 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
How do I buy shares of Trillium Therapeutics?
Shares of TR and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Trillium Therapeutics' stock price today?
One share of TR stock can currently be purchased for approximately C$30.20.
How big of a company is Trillium Therapeutics?
Trillium Therapeutics has a market capitalization of C$136.73 million.
How can I contact Trillium Therapeutics?
Trillium Therapeutics' mailing address is 2488 Dunwin Dr, MISSISSAUGA, ON L5L 1J9, Canada. The company can be reached via phone at +1-416-5950627.
MarketBeat Community Rating for Trillium Therapeutics (TR)
MarketBeat's community ratings are surveys of what our community members think about Trillium Therapeutics and other stocks. Vote "Outperform" if you believe TR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Trillium Therapeutics (TSE:TR) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Trillium Therapeutics in the last 12 months. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.50 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | N/A |
| Price Target Upside: | N/A | N/A | N/A | N/A |
Trillium Therapeutics (TSE:TR) Consensus Price Target History
Trillium Therapeutics (TSE:TR) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Trillium Therapeutics (TSE:TR) Earnings History and Estimates Chart
Trillium Therapeutics (TSE TR) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/11/2018 | | | | | | | | |
| 3/9/2018 | Q4 2017 | C($1.06) | C($0.91) | | | View | N/A |  |
| 11/10/2017 | Q3 2017 | C($1.08) | C($1.05) | | | View | N/A | |
| 8/11/2017 | Q2 2017 | C($1.26) | C($1.33) | | | View | N/A | |
| 5/12/2017 | Q1 2017 | | C$1.46 | | | View | N/A | |
| 3/10/2017 | Q4 2016 | | C($1.46) | | | View | N/A | |
| 11/10/2016 | Q3 2016 | | C($1.01) | | | View | N/A | |
| 8/12/2016 | Q2 2016 | | C($0.97) | | | View | N/A | |
| 5/13/2016 | Q1 2016 | | C($0.92) | | | View | N/A | |
| 3/9/2016 | Q4 2015 | | C($0.38) | | | View | N/A | |
| 11/10/2015 | Q3 2015 | | C($0.21) | | | View | N/A | |
| 8/11/2015 | Q2 2015 | | C($0.80) | | | View | N/A | |
| 5/13/2015 | Q1 2015 | | C($0.98) | | | View | N/A | |
| 3/24/2015 | Q4 2014 | | C($0.97) | | | View | N/A | |
| 11/13/2014 | Q3 2014 | | C($0.60) | | | View | N/A | |
| 8/12/2014 | Q2 2014 | | C($0.90) | | | View | N/A | |
| 5/12/2014 | Q1 2014 | | C($0.60) | | | View | N/A | |
| 3/28/2014 | Q4 2013 | | C($0.60) | | | View | N/A | |
| 11/1/2013 | Q3 2013 | | C($0.90) | | | View | N/A | |
| 8/27/2013 | Q2 2013 | | C($0.90) | | | View | N/A | |
| 5/24/2013 | Q1 2013 | | C($0.60) | | | View | N/A | |
| 8/22/2012 | Q2 2012 | | C($0.60) | | | View | N/A | |
| 5/22/2012 | Q1 2012 | | C($0.60) | | | View | N/A | |
| 4/26/2012 | Q4 2011 | | C($3.00) | | | View | N/A | |
| 8/25/2010 | Q2 2010 | | C($3.00) | | | View | N/A | |
| 4/13/2010 | Q4 2009 | | C($1.50) | | | View | N/A | |
| 5/27/2009 | Q1 2009 | | C($3.00) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Trillium Therapeutics (TSE:TR) Dividend Information
Trillium Therapeutics pays an annual dividend of C$0.36 per share, with a dividend yield of 1.19%.
| Annual Dividend: | $0.36 |
| Dividend Yield: | 1.19% |
| Payout Ratio: | N/A |
Trillium Therapeutics (TSE:TR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Trillium Therapeutics (TSE TR) Insider Trading and Institutional Ownership History
Trillium Therapeutics (TSE TR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/22/2016 | Calvin R Stiller | Director | Buy | 9,000 | C$11.11 | C$100,026.00 | | |
| 3/21/2016 | Eric L Sievers | Insider | Buy | 23,020 | C$8.21 | C$188,994.20 | | |
(Data available from 1/1/2013 forward)
Trillium Therapeutics (TSE TR) News Headlines
| Source: |
|
Trillium Therapeutics (TSE:TR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Trillium Therapeutics (TSE TR) Stock Chart for Saturday, April, 21, 2018
Loading chart…
